The newest product lines are:
1. Traditional bone allograft, featuring cancellous chips, demineralized cancellous chips, cortical cancellous chips and cancellous crushed. The allograft can be packed into bony voids or gaps in a patient’s skeletal system and is available in several grind sizes and volumes.
2. Amniotic membrane DS, a double-sided layer of human amniotic membrane designed to be a biologic barrier to help prevent adhesions and reduce scar tissue formation near adjacent muscle, nerve and fascia layer tissue.
3. Additional form factors to the Propel DBM product line, which now includes gel, gel plus and putty plus as additional form factors with enhanced handling properties. The additional DBM form factors are intended to enable surgeons to tailor graft selection to the patient’s needs.
NuVasive’s newest biologic product lines are intended to improve patient outcomes and economic outcomes for hospital systems as well as meet spine surgeon’s handling preferences.
More articles on biologics:
Regenexx makes new partnership to reduce musculoskeletal surgery costs
10 leading players in the global orthopedic biomaterials market
Bioengineered ACL implant startup raises $22.5M: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
